Professional Documents
Culture Documents
Colistin: How Should It Be Dosed For The Critically Ill?: Cornelia B. Landersdorfer, PHD Roger L. Nation, PHD
Colistin: How Should It Be Dosed For The Critically Ill?: Cornelia B. Landersdorfer, PHD Roger L. Nation, PHD
Abstract
Keywords
colistin
critically ill
polymyxins
colistin
methanesulfonate
pharmacokinetics
pharmacodynamics
toxicodynamics
optimized dosing
DOI http://dx.doi.org/
10.1055/s-0034-1398390.
ISSN 1069-3424.
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Landersdorfer, Nation
Vol. 36
No. 1/2015
127
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Landersdorfer, Nation
Vol. 36
No. 1/2015
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
128
Landersdorfer, Nation
Vol. 36
No. 1/2015
129
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Landersdorfer, Nation
Fig. 2 Plasma concentrations of colistin methanesulfonate (CMS) (panels A and C) and formed colistin (panels B and D) in individual critically ill
patients after the administration of the rst dose of CMS (left panels) and the fourth dose of CMS (right panels). The dose of CMS was 3 million IU
(90 mg colistin base activity [CBA]) every 8 hours in all except one patient who received 2 million IU (60 mg CBA) every 8 hours. Adapted with
permission from Plachouras et al. 48
colistin was considerably longer at 18.5 hours. A comprehensive search for patient covariates (e.g., body weight, renal
function) that may inuence the disposition of CMS and/or
colistin was conducted by the authors. However, no covariates were identied, most likely because of the small sample
size (total of 28 patients across the two studies) and only 3 of
these patients had a creatinine clearance less than 50 mL/min.
Garonzik et al50 reported the results of the largest study
thus far on the PK of CMS and colistin in critically ill patients.
The study population was 105 patients, including 89 not on
renal replacement who had a large range of renal function
(creatinine clearance 3169 mL/[min1.73 m2]), 12 on intermittent hemodialysis and 4 on continuous renal replacement
Fig. 3 Plasma concentration versus time proles of the prodrug colistin methanesulfonate (CMS) (panel A) and formed colistin (panel B) across a
dosage interval at steady state in 105 critically ill patients (89 not on renal replacement, 12 on intermittent hemodialysis, and 4 on continuous
renal replacement therapy). Physician-selected CMS dosage intervals ranged from 8 to 24 hour and hence the interdosing blood sampling interval
spanned the same range. Reproduced with permission from Garonzik et al.50
Seminars in Respiratory and Critical Care Medicine
Vol. 36
No. 1/2015
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
130
Landersdorfer, Nation
Fig. 4 Relationship of physician-selected daily dose of CMS (expressed as colistin base activity [CBA]) (panel A) and the resultant steady-state
plasma colistin concentration (panel B) with creatinine clearance in 105 critically ill patients. Reproduced with permission from Garonzik et al. 50
Vol. 36
No. 1/2015
131
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Landersdorfer, Nation
Vol. 36
No. 1/2015
Take-Home Messages
The following are some key points for those using colistin in
critically ill patients to keep in mind:
How is colistin administered? Colistin is administered
intravenously and by inhalation as its inactive prodrug
CMS (also known as colistimethate). CMS must be converted to colistin in the body. Care is needed to avoid
confusion arising from the different conventions used to
label vials and specify doses.
What plasma concentration is appropriate for intravenous
administration? Based upon current evidence, a plasma
colistin concentration of 2 mg/L is a reasonable target
value for isolates with MICs 1 mg/L, and minimizes the
risk of nephrotoxicity.
Should I consider colistin combination therapy? It is prudent
to consider combination therapy for infections where the
causative organism has an MIC > 1 mg/L or when there is
a high-inoculum or deep-seated infection (e.g., in lungs),
especially in patients with moderate-to-good renal function, although the clinical benet of colistin combinations
remains unproven.
Do I need to administer an intravenous loading dose? Yes,
because CMS is relatively slowly converted to colistin in the
body and it may take many hours to achieve steady-state
plasma concentrations without a loading dose.
Do I need to adjust the daily maintenance dose if the patient
has renal impairment? The plasma concentrations of
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
132
10
11
12
13
14
15
16
17
Acknowledgment
This work was supported by the Australian National
Health and Medical Research Council (NHMRC, Career
Development fellowship number 1062509 to C. B. L.).
18
19
References
1 Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton
3
4
5
20
21
22
23
24
Landersdorfer, Nation
dosing for patients who are critically ill: challenges and potential
solutions. Lancet Infect Dis 2014;14(6):498509
Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. Old antibiotics
for emerging multidrug-resistant bacteria. Curr Opin Infect Dis
2012;25(6):626633
Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and
pharmacodynamics of old polymyxins: what is new? Diagn
Microbiol Infect Dis 2012;74(3):213223
Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of
colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25(1):1125
Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is
an inactive prodrug of colistin against Pseudomonas aeruginosa.
Antimicrob Agents Chemother 2006;50(6):19531958
Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br Pharmacol Chemother 1964;23:552574
Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of
colistin and colistin methanesulfonate in aqueous media and
plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003;47(4):13641370
Dudhani RV, Nation RL, Li J. Evaluating the stability of colistin and
colistin methanesulphonate in human plasma under different
conditions of storage. J Antimicrob Chemother 2010;65(7):
14121415
Nation RL, Li J, Cars O, et al. Consistent global approach on
reporting of colistin doses to promote safe and effective use.
Clin Infect Dis 2014;58(1):139141
Institute for Safe Medication Practices (ISMP). National alert
issued: Dosing confusion with colistimethate for injection, 2011.
Available at: http://www.ismp.org/pressroom/PR20110629.pdf.
Accessed 24 August, 2014
Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and
polymyxin B against a worldwide collection of Gram-negative
pathogens: results from the SENTRY Antimicrobial Surveillance
Program (2006-09). J Antimicrob Chemother 2011;66(9):
20702074
Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America:
results from SENTRY Antimicrobial Surveillance Program (Latin
America, 2008-2010). Diagn Microbiol Infect Dis 2012;73(4):
354360
Hawser SP. Susceptibility of Klebsiella pneumoniae clinical isolates
from 2007 to 2009 to colistin and comparator antibiotics. Int
J Antimicrob Agents 2010;36(4):383384
Nakamura T, Komatsu M, Yamasaki K, et al. Susceptibility of
various oral antibacterial agents against extended spectrum
-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Infect Chemother 2014;20(1):4851
The European Committee on Antimicrobial Susceptibility Testing.
Breakpoint tables for interpretation of MICs and zone diameters.
Version 4.0 2014. Available at: http://www.eucast.org. Accessed
24 August, 2014
Clinical and Laboratory Standards Institute (CLSI). Performance
standards for antimicrobial susceptibility testing; twenty-third
informational supplement. 2013
Velkov T, Thompson PE, Nation RL, Li J. Structureactivity relationships of polymyxin antibiotics. J Med Chem 2010;53(5):
18981916
Hancock RE. Alterations in outer membrane permeability. Annu
Rev Microbiol 1984;38:237264
Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in
Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;
54(12):49714977
Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate
against Pseudomonas aeruginosa isolates from patients with
Vol. 36
No. 1/2015
133
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Landersdorfer, Nation
Vol. 36
No. 1/2015
41 Clancy CJ, Chen L, Hong JH, et al. Mutations of the ompK36 porin
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
gene and promoter impact responses of sequence type 258, KPC-2producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 2013;57(11):
52585265
Zusman O, Avni T, Leibovici L, et al. Systematic review and metaanalysis of in vitro synergy of polymyxins and carbapenems.
Antimicrob Agents Chemother 2013;57(10):51045111
Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy
for carbapenem-resistant Gram-negative bacteria. J Antimicrob
Chemother 2014;69(9):23052309
Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K.
Use of high-performance liquid chromatography to study the
pharmacokinetics of colistin sulfate in rats following intravenous
administration. Antimicrob Agents Chemother 2003;47(5):
17661770
Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K.
Pharmacokinetics of colistin methanesulphonate and colistin in
rats following an intravenous dose of colistin methanesulphonate.
J Antimicrob Chemother 2004;53(5):837840
Marchand S, Lamarche I, Gobin P, Couet W. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in
rats following single intravenous CMS doses. J Antimicrob Chemother 2010;65(8):17531758
Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of
intravenous colistin methanesulphonate in patients with cystic
brosis. J Antimicrob Chemother 2003;52(6):987992
Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after
intravenous administration in critically ill patients with infections
caused by gram-negative bacteria. Antimicrob Agents Chemother
2009;53(8):34303436
Couet W, Grgoire N, Gobin P, et al. Pharmacokinetics of colistin
and colistimethate sodium after a single 80-mg intravenous dose
of CMS in young healthy volunteers. Clin Pharmacol Ther 2011;
89(6):875879
Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically
ill patients from a multicenter study provide dosing suggestions
for various categories of patients. Antimicrob Agents Chemother
2011;55(7):32843294
Theuretzbacher U. Product information for parenteral colistin
varies substantially across Europe. J Antimicrob Chemother
2014;69(7):19871992
Nation RL, Velkov T, Li J. Colistin and Polymyxin B: Peas in a Pod, or
Chalk and Cheese? Clin Infect Dis 2014
Antachopoulos C, Karvanen M, Iosidis E, et al. Serum and
cerebrospinal uid levels of colistin in pediatric patients. Antimicrob Agents Chemother 2010;54(9):39853987
Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin
methanesulfonate and colistin in a critically ill patient receiving
continuous venovenous hemodialtration. Antimicrob Agents
Chemother 2005;49(11):48144815
Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic
dosing in critically ill adult patients receiving continuous renal
replacement therapy. Clin Infect Dis 2005;41(8):11591166
Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum
concentrations after intravenous administration in critically ill
patients with serious multidrug-resistant, gram-negative bacilli
infections: a prospective, open-label, uncontrolled study. Clin Ther
2008;30(1):143151
Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics
and BAL concentration of colistin in critically Ill patients after IV
colistin methanesulfonate administration. Chest 2010;138(6):
13331339
Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a
loading dose of colistin methanesulfonate in critically ill patients:
population pharmacokinetics, protein binding, and prediction of
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
134
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
Landersdorfer, Nation
Vol. 36
No. 1/2015
135
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.